Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Net Income (2022 - 2025)

Historic Net Income for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $42.0 million.

  • Indivior Pharmaceuticals' Net Income rose 9090.91% to $42.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.0 million, marking a year-over-year increase of 13888.89%. This contributed to the annual value of $7.0 million for FY2024, which is 10555.56% up from last year.
  • Latest data reveals that Indivior Pharmaceuticals reported Net Income of $42.0 million as of Q3 2025, which was up 9090.91% from $18.0 million recorded in Q2 2025.
  • Over the past 5 years, Indivior Pharmaceuticals' Net Income peaked at $85.0 million during Q2 2023, and registered a low of -$329.0 million during Q4 2022.
  • For the 4-year period, Indivior Pharmaceuticals' Net Income averaged around -$5.8 million, with its median value being $45.0 million (2025).
  • The largest annual percentage gain for Indivior Pharmaceuticals' Net Income in the last 5 years was 12066.87% (2023), contrasted with its biggest fall of 43880.6% (2023).
  • Indivior Pharmaceuticals' Net Income (Quarter) stood at -$329.0 million in 2022, then soared by 120.67% to $68.0 million in 2023, then crashed by 69.12% to $21.0 million in 2024, then surged by 100.0% to $42.0 million in 2025.
  • Its last three reported values are $42.0 million in Q3 2025, $18.0 million for Q2 2025, and $48.0 million during Q1 2025.